I spent a good chunk of this past week at BioFinance in Toronto, where I spoke about public market strategies for cleantech and blogged about the keynote address by Scott Gottlieb, an ex-FDA official now at the American Enterprise Institute, who talked about follow-on biologics, comparative effectiveness, and the regulatory environment at the FDA.
In the real world, Swine Flu continued to spread but turned out not to be as virulent as we first thought, at least for now. We also learned that the party is over for medical imaging in the U.S. and for . . . [more]